Ligand Pharmaceuticals Inc.
CIK: 0000886163
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Pelthos Therapeutics Inc.
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Dec 17, 2025PTHS
Pelthos Therapeutics Inc.
Disposition(D)DirectSenior Secured Convertible Note
0 shares- - Dec 17, 2025PTHS
Pelthos Therapeutics Inc.
Award(A)DirectSenior Secured Convertible Note
0 shares- - Nov 6, 2025PTHS
Pelthos Therapeutics Inc.
Award(A)DirectSenior Secured Convertible Note
0 shares at avg. $9000000.00- - Jul 1, 2025PTHS
Pelthos Therapeutics Inc.
Conversion(C)Direct1.5M shares at avg. $10.00$15.0M - Jul 1, 2025PTHS
Pelthos Therapeutics Inc.
Other(J)DirectSeries A Convertible Preferred Stock
31.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Dec 17, 2025 | PTHS Pelthos Therapeutics Inc. | Disposition(D) Senior Secured Convertible Note | 0 | - | - | Direct |
| Dec 17, 2025 | PTHS Pelthos Therapeutics Inc. | Award(A) Senior Secured Convertible Note | 0 | - | - | Direct |
| Nov 6, 2025 | PTHS Pelthos Therapeutics Inc. | Award(A) Senior Secured Convertible Note | 0 | $9000000.00 | - | Direct |
| Jul 1, 2025 | PTHS Pelthos Therapeutics Inc. | Conversion(C) | 1,500,000 | $10.00 | $15,000,000 | Direct |
| Jul 1, 2025 | PTHS Pelthos Therapeutics Inc. | Other(J) Series A Convertible Preferred Stock | 31,279 | - | - | Direct |
1-5 of 5 transactions
About LIGAND PHARMACEUTICALS INC
LIGAND PHARMACEUTICALS INC (SEC CIK 0000886163) files insider reports with the SEC as 10% Owner of Pelthos Therapeutics Inc. (PTHS).
Signal8 holds 4 ownership filings by LIGAND PHARMACEUTICALS INC (1 Form 3, 3 Form 4), filed between Jul 3, 2025 and Dec 19, 2025. Those filings report 5 transactions, from Jul 1, 2025 to Dec 17, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on LIGAND PHARMACEUTICALS INC's filings is in JUPITER, FL.
Recent filings by LIGAND PHARMACEUTICALS INC
- Dec 17, 2025: Disposition to issuer transaction of PTHS derivative securities (Form 4, code D).
- Dec 17, 2025: Grant or award of PTHS derivative securities (Form 4, code A).
- Nov 6, 2025: Grant or award of PTHS derivative securities (Form 4, code A).
- Jul 1, 2025: Conversion of PTHS shares (Form 4, code C).
- Jul 1, 2025: Other transaction of PTHS derivative securities (Form 4, code J).
Other insiders filing for Pelthos Therapeutics Inc. (PTHS)
- Greenleaf Peter, Director
- Friedberg Ezra M, Director
- Pauls Matthew, Director
- Davis Todd C, Director
- Francis Knuettel II, CFO, Treas & Secty
- GAY JOHN M., Chief Financial Officer